Product Development Partnerships Hit Their Stride: Lessons from Developing a Meningitis Vaccine for Africa
This article, published in Health Affairs, provides an overview of the Meningitis Vaccine Project as an example of how product development partnerships have reinvigorated research on vaccines for neglected diseases. The Meningitis Vaccine Project developed a new vaccine against bacterial meningitis—known as MenAfriVac™ and specifically targeted for use in low-income countries in Africa—which was designed to be made available to governments at a price of fifty cents per dose. The vaccine was rapidly embraced by African health officials, and in its first few weeks on the market, in late 2010, more than nineteen million people in Burkina Faso, Mali, and Niger were vaccinated. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Bishai DM, Champion C, Steele ME, Thompson L
Visit web page (English)
(Located at content.healthaffairs.org)
Citation: Bishai DM, Champion C, Steele ME, Thompson L. Product Development Partnerships Hit Their Stride: Lessons from Developing a Meningitis Vaccine for Africa. Health Affairs. 2011;30(6):1058-1064.